Similar Evolution of Cellular HIV-1 DNA Level in DarunavirRitonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks 英文参考文献.docVIP

下载本文档

2
0
约1.9万字
约 5页
2017-05-13 发布于上海
举报
版权申诉

Similar Evolution of Cellular HIV-1 DNA Level in DarunavirRitonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Similar Evolution of Cellular HIV-1 DNA Level in DarunavirRitonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks 英文参考文献

SimilarEvolutionofCellularHIV-1DNALevelin Darunavir/RitonavirMonotherapyversusTripleTherapy inMONOI–ANRS136Trialover96Weeks SidonieLambert-Niclot1*,PhilippeFlandre1,Marc-AntoineValantin1,CathiaSoulie1,SlimFourati1, MarcWirden1,SophieSayon1,SophiePakianather2,LaurenceBocket3,BernardMasquelier4, GeorgesDosSantos5,ChristineKatlama1,VincentCalvez1,Anne-GenevieveMarcelin1 1AP-HP,Pitie′-Salpe?trie`re Hospital,INSERMU943andPierreetMarieCurieUniversityParis,Paris,France,2INSERMU943,Paris,France,3CHRUdeLille,Virology,Lille, France,4AP-HP,PellegrinHospital,Bordeaux,France,5CentreHospitalieretUniversitairedeFort-de-France,FortdeFrance,Martinique,France Abstract Background:Ahigherproportionofintermittentviremia(tohaveaHIV-1RNAviralload.50copies/mLnotconfirmed)was reportedintheboostedproteaseinhibitormonotherapyarminsomestudiesincludingMONOItrial,andthatcouldhavean impactonthereplenishmentoftheHIV-1DNAreservoirs.TheHIV-1DNAlevelisaninterestingmarkerwhichreflectsthe size of cellular HIV reservoir. Our objectives were to study the impact of 96 weeks of Darunavir/ritonavir monotherapy versusatriplestandardcombinationontheHIV-1bloodreservoirandfactorsassociatedwithHIV-1plasmaDNAatbaseline inMONOItrialsub-study. Methodology/Principal Findings: This sub-study is focused on 160patients (79patients in monotherapy arm and81 in tritherapyarm)forwhombloodcellswereavailablebothatbaselineandatweek96(W96).BaselineHIV-1plasmaDNAwas associatedwithCD4nadir,pretherapeuticHIV-1RNAviralloadandbaselineHIV-1RNAmeasuredbyultrasensitiveassay.A similar median delta HIV-DNA was observed between D0 and W96 in both arms; 0.35 log copies/106 leucocytes in monotherapyarmversus0.51logcopies/106leucocytesintritherapyarm. Conclusion/Significance: Despiteahigherproportionofintermittentviremiainmonotherapyarm,asimilarevolutionof cellularHIV-1DNAlevelwasobservedbetweenmonoandtripletherapyarm. TrialRegistration:ClinicalTNCCitation: Lambert-Niclot S, Flandre P, Valantin M-A, Soulie C, Fourati S, et al.